Published: Sep-16-2022
Cend Therapeutics, spin-out company of BICI's sponsored
research project "iRGD targeted drug delivery system for precise tumor
diagnosis and treatment" has announced the merger with Caladrius
Biosciences on September 15, 2022. The merged company will now operate as
Lisata Therapeutics, Inc. and will commence trading on The Nasdaq Capital
Market under the ticker symbol “LSTA”.
For detailed press release announcement, please go to https://ir.caladrius.com/news-releases/news-release-details/caladrius-biosciences-and-cend-therapeutics-announce-closing